Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 4Phase 1/2 4Phase 1 3Phase 2/3 1

Status

Completed 4Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 32Breast Neoplasms 25Parkinson Disease 4, Autosomal Dominant Lewy Body 18Multiple Myeloma 13Neoplasms 12Leukemia, Myeloid, Acute 12Ovarian Neoplasms 10Neoplasm Metastasis 10Leukemia, Lymphocytic, Chronic, B-Cell 10Carcinoma, Renal Cell 9Prostatic Neoplasms 8Colorectal Neoplasms 8Melanoma 7Lymphoma, Non-Hodgkin 7Leukemia 7Stomach Neoplasms 6Recurrence 6Fallopian Tube Neoplasms 6Carcinoma, Hepatocellular 6Carcinoma 6Urinary Bladder Neoplasms 5Small Cell Lung Carcinoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma 5Adenocarcinoma 5Purpura, Thrombocytopenic, Idiopathic 4Myelodysplastic Syndromes 4Lymphoma, Follicular 4Liver Neoplasms 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4

Interventions

zanubrutinib 1selinexor 1niraparib 1ibrutinib 1dostarlimab 1blinatumomab 1Standard of Care 1Paclitaxel 1Drug Therapy 1Dexamethasone 1Carboplatin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Has announcements × Recurrence × Clear all
NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting
785 enrolled 2 FDA

Neoplasms, Recurrence

NCT03581786 2025-09-02

The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 3 Completed
289 enrolled 32 charts 1 FDA

Recurrence

NCT03575351 2025-08-03

TRANSFORM

Celgene

Phase 3 Completed
184 enrolled 30 charts 1 FDA
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

NCT03734016 2025-03-30

ALPINE

BeiGene

Phase 3 Completed
652 enrolled 27 charts 1 FDA
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03110562 2024-08-21

BOSTON

Karyopharm Therapeutics Inc

Phase 3 Completed
402 enrolled 22 charts 1 FDA
Plasma cell

Multiple Myeloma, Recurrence

NCT02013167 2024-03-05

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Terminated
405 enrolled 27 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡